MAPT and amyloidosis: These findings are timely given the anticipated Revised Criteria for Diagnosis and Staging of AD from the Alzheimer’s Association Work Group, which at present proposes that elevated plasma P-tau217 is sufficient to fulfill Core 1 criteria for A (amyloidosis) and T1 (secreted phosphorylated tau fragments) for a biomarker diagnosis of AD [28].